Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.006
Sell
RSI(14)
35.328
Neutral
STOCH(KDJ)(9,3,3)
21.709
Neutral
ATR(14)
0.032
Low Volatility
CCI(14)
-118.444
Sell
Williams %R
86.465
Oversold
TRIX(12,20)
-0.643
Sell
StochRSI(14)
0.000
Sell
Cue Biopharma Inc
CUE0.220USD
-0.019-7.98%
Market hours （ET）Quotes delayed by 15 min
3.67MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Cue Biopharma Inc
Currency: USD Updated: 2026-03-27Key Insights
Cue Biopharma Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 151 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Cue Biopharma Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Cue Biopharma Inc Highlights
StrengthsRisks
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 400.29% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 27.47M.
Overvalued
The company’s latest PE is -0.85, at a high 3-year percentile range.
Held by James Simons
Star Investor James Simons holds 238.35K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.71.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
4.000
Target Price
+1494.26%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-27The current financial score of Cue Biopharma Inc is 7.16, ranking 120 out of 391 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 21.94M, representing a year-over-year increase of 1292.26%, while its net profit experienced a year-over-year increase of 116.69%.
Score
Financials
6.73
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
8.39
Operational Efficiency
3.14
Growth Potential
10.00
Shareholder Returns
7.54
Cue Biopharma Inc's Company Valuation
Currency: USD Updated: 2026-03-27The current valuation score of Cue Biopharma Inc is 7.34, ranking 129 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.85, which is -45.24% below the recent high of -0.47 and -334.11% above the recent low of -3.70.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 151/391
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-27The current earnings forecast score of Cue Biopharma Inc is 8.00, ranking 163 out of 391 in the Biotechnology & Medical Research industry. The average price target is 5.00, with a high of 6.00 and a low of 4.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
4.000
Target Price
+1494.26%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
548
Total
6
Median
6
Average
Company name
Ratings
Analysts
Cue Biopharma Inc
CUE
1
CRISPR Therapeutics AG
CRSP
29
IQVIA Holdings Inc
IQV
27
argenx SE
ARGX
26
Intellia Therapeutics Inc
NTLA
24
Beigene Ltd
ONC
24
1
2
3
...
110
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-27The current price momentum score of Cue Biopharma Inc is 4.93, ranking 332 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.32 and the support level at 0.19, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
0.255
Sell
MA10
0.265
Sell
MA20
0.282
Sell
MA50
0.305
Sell
MA100
0.398
Sell
MA200
0.583
Sell
Institutional Confidence
Currency: USD Updated: 2026-03-27The current institutional shareholding score of Cue Biopharma Inc is 3.00, ranking 195 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 28.38%, representing a quarter-over-quarter decrease of 4.39%. The largest institutional shareholder is The Vanguard, holding a total of 3.01M shares, representing 3.09% of shares outstanding, with 17.62% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Bleichroeder LP
Catalytic Wealth RIA, LLC
Geode Capital Management, L.L.C.
Boothbay Fund Management, LLC
Robertson Stephens Wealth Management, LLC
BlackRock Institutional Trust Company, N.A.
Sarraf (Pasha)
1
2
Risk Assessment
Currency: USD Updated: 2026-03-27The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Cue Biopharma Inc is 1.49, ranking 304 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 1.53. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.54
VaR
+8.45%
240-Day Maximum Drawdown
+74.16%
240-Day Volatility
+119.17%
Return
Best Daily Return
60 days
+25.69%
120 days
+34.77%
5 years
+49.61%
Worst Daily Return
60 days
-18.77%
120 days
-21.58%
5 years
-24.62%
Sharpe Ratio
60 days
-0.09
120 days
-1.49
5 years
-0.41
Risk Assessment
Maximum Drawdown
240 days
+74.16%
3 years
+94.90%
5 years
+98.66%
Return-to-Drawdown Ratio
240 days
-0.93
3 years
-0.33
5 years
-0.20
Skewness
240 days
+1.16
3 years
+1.94
5 years
+1.63
Volatility
Realised Volatility
240 days
+119.17%
5 years
+108.38%
Standardised True Range
240 days
+23.26%
5 years
+117.45%
Downside Risk-Adjusted Return
120 days
-243.22%
240 days
-243.22%
Maximum Daily Upside Volatility
60 days
+102.62%
Maximum Daily Downside Volatility
60 days
+69.54%
Liquidity
Average Turnover Rate
60 days
+0.52%
120 days
+0.40%
5 years
--
Turnover Deviation
20 days
-70.81%
60 days
-24.82%
120 days
-42.77%
Peer Comparison
Biotechnology & Medical Research
Cue Biopharma Inc
CUE
5.93 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Madrigal Pharmaceuticals Inc
MDGL
8.27 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.27 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Day One Biopharmaceuticals Inc
DAWN
8.26 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.21 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
